Omeros' (OMER) "Neutral" Rating Reiterated at Cantor Fitzgerald

Cantor Fitzgerald restated their neutral rating on shares of Omeros (NASDAQ:OMER - Free Report) in a report released on Thursday,Benzinga reports.

Several other equities analysts also recently weighed in on OMER. Rodman & Renshaw began coverage on Omeros in a research report on Thursday. They issued a "buy" rating and a $9.00 target price on the stock. Needham & Company LLC reissued a "hold" rating on shares of Omeros in a research note on Thursday. Finally, StockNews.com downgraded shares of Omeros from a "hold" rating to a "sell" rating in a research note on Tuesday.

Omeros Stock Up 65.9 %

Shares of Omeros stock traded up $2.76 during trading on Thursday, reaching $6.95. The company's stock had a trading volume of 14,188,513 shares, compared to its average volume of 459,374. Omeros has a 1-year low of $1.38 and a 1-year high of $7.51. The company has a 50-day simple moving average of $4.02 and a two-hundred day simple moving average of $4.05. The company has a market cap of $402.75 million, a price-to-earnings ratio of -2.23 and a beta of 1.47.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in OMER. BNP Paribas Financial Markets increased its holdings in shares of Omeros by 75.5% during the 1st quarter. BNP Paribas Financial Markets now owns 30,102 shares of the biopharmaceutical company's stock worth $104,000 after buying an additional 12,951 shares during the last quarter. Oppenheimer & Co. Inc. acquired a new stake in shares of Omeros during the first quarter worth approximately $85,000. Comerica Bank raised its stake in shares of Omeros by 20.0% in the 1st quarter. Comerica Bank now owns 30,000 shares of the biopharmaceutical company's stock valued at $104,000 after purchasing an additional 5,000 shares in the last quarter. Vanguard Group Inc. increased its holdings in shares of Omeros by 2.6% in the 1st quarter. Vanguard Group Inc. now owns 3,250,284 shares of the biopharmaceutical company's stock valued at $11,213,000 after acquiring an additional 81,348 shares during the last quarter. Finally, Bank of New York Mellon Corp lifted its stake in Omeros by 16.6% during the second quarter. Bank of New York Mellon Corp now owns 218,580 shares of the biopharmaceutical company's stock worth $887,000 after purchasing an additional 31,081 shares during the last quarter. 48.79% of the stock is currently owned by hedge funds and other institutional investors.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.